Home  >  Speakers  >  Andrew Tutt
Andrew Tutt

Andrew Tutt

    MB ChB, PhD, MRCP, FRCR
Professor, Consultant | London, England    United Kingdom
Oncology
Oncology, Breast Cancer,...More
Spoken at 4 events

Biography :

Professor Andrew Tutt qualified in medicine in 1990. After postgraduate training in General Medicine, he trained in clinical oncology at the The Royal Marsden NHS Foundation Trust before gaining a Doctoral Research Training Fellowship from the Medical Research Council to work in Professor Alan Ashworth’s laboratory at The Institute of Cancer Research, London.
Here, he worked on the then-unknown DNA repair functions of the BRCA2 breast cancer predisposition gene and was awarded his PhD in 2002. In his postdoctoral work as a Clinician Scientist he identified the synthetic lethality between PARP inhibitors and BRCA1/2 mutations with Dr Chris Lord and Professor Alan Ashworth. He went on to design the Single Agent Proof of Concept Phase I trials and associated DNA repair biomarker studies with the ICR and The Royal Marsden Drug Development Unit, and has since led international Phase II and III trials for BRCA1/BRCA2-associated malignancy.
He cares for women with breast cancer as a Consultant Oncologist in the multidisciplinary Breast Unit at Guy’s and St Thomas’ NHS Foundation Trust. He is Professor of Breast Oncology and Director of the Breast Cancer Now Research Unit at King’s College London and has recently been appointed Director of the Breast Cancer Now Toby Robins Research Centre, Head of the Division of Breast Cancer Research and Professor of Breast Oncology at the ICR.
Professor Tutt has developed a translational laboratory for triple negative breast cancer. He leads a clinical trial programme focusing on TNBC and cancers associated with functional deficiencies in BRCA1 and BRCA2. He also leads translational laboratories at both the ICR and KCL, studying BRCA1 and BRCA2 associated TNBC forms of breast cancer. Andrew’s group publishes in high impact journals regularly and amongst their latest work they published a new TNBC target, PIM1 kinase, in Nature Medicine in November 2016.

*********************
*** ***** **** ****
This section has yet to be updated by the speaker.
For speaker's contact information - Contact us

Specialties

Oncology

Interested Topics

Oncology, Breast Cancer, Biomarkers, Clinical Trials, Translational Research, Triple negative breast cancers, Drug Development, Radiation Therapy, Brian Tumor

State Licenses

This section has yet to be updated by the speaker.

Board Certifications

This section has yet to be updated by the speaker.

Professional Association

This section has yet to be updated by the speaker.

Languages

English

Conference Session Materials

The conference session material has yet to be added by the speaker.
X

Send Message

Convert
Onsite to Virtual Conference

Market your online event to Million plus Healthcare professionals.